Core Viewpoint - The latest holdings of Central Huijin Investment in major ETFs have been disclosed, indicating stable positions in various funds despite recent net outflows from the ETF market [1][4]. Group 1: Central Huijin Holdings - As of the end of 2025, Central Huijin Asset Management holds 378.58 billion shares and Central Huijin Investment holds 356.55 billion shares of the Huatai-PB CSI 300 ETF [1][2]. - The total holdings of Central Huijin in the Huatai-PB CSI 300 ETF represent 40.26% and 37.91% of the total shares, respectively [3]. Group 2: ETF Market Trends - The ETF market has experienced significant net outflows, with over 220 billion yuan leaving the CSI 300 theme ETFs and more than 570 billion yuan from the CSI 1000 theme ETFs from January 12 to January 21 [4]. - As of January 21, the total shares of leading ETFs such as Huatai-PB CSI 300 ETF and others have decreased compared to the end of 2025, indicating a decline in market interest [4][6]. Group 3: Comparison of ETF Holdings - The latest share counts for various ETFs as of January 21 are below the holdings reported by Central Huijin at the end of 2025, including Huatai-PB CSI 300 ETF at 719.78 billion shares compared to 735.13 billion shares [5][6]. - Other ETFs like E Fund CSI 300 ETF and Huaxia CSI 300 ETF also show a decline in shares compared to Central Huijin's previous holdings [5][6].

Core Viewpoint - The article discusses the latest holdings of major broad-based ETFs, particularly focusing on the Central Huijin's investment positions as of the end of 2025, revealing significant data on fund holdings and net outflows in the ETF market [2][6]. Group 1: Central Huijin Holdings - As of the end of 2025, Central Huijin Asset Management Co., Ltd. held 378.58 billion shares and Central Huijin Investment Co., Ltd. held 356.55 billion shares of the Huatai-PineBridge CSI 300 ETF [2][4]. - The holdings of Central Huijin in the Huatai-PineBridge CSI 300 ETF remained unchanged in the second half of 2025 compared to the first half [5]. Group 2: ETF Market Trends - The broad-based ETFs have experienced significant net outflows recently, with the CSI 300 theme ETFs seeing a net outflow of over 220 billion yuan from January 12 to January 21, 2025 [6]. - Other ETFs, including the CSI 1000 theme ETFs and the Shanghai Stock Exchange 50 theme ETFs, also faced substantial net outflows, indicating a broader trend in the market [6]. - As of January 21, 2025, the total shares of leading broad-based ETFs such as Huatai-PineBridge CSI 300 ETF and others have decreased compared to the holdings reported by Central Huijin at the end of 2025 [6][7].

Core Insights - The latest holdings of Central Huijin have been revealed following the disclosure of the 2025 Q4 reports of leading broad-based ETFs, with significant positions in the Huatai-PB CSI 300 ETF [1][3] Holdings Summary - As of the end of 2025, Central Huijin Asset Management Co., Ltd. held 378.58 billion shares, while Central Huijin Investment Co., Ltd. held 356.55 billion shares of the Huatai-PB CSI 300 ETF [1][4] - The shareholding proportions for Central Huijin Asset Management and Central Huijin Investment are 40.26% and 37.91%, respectively [4] Comparison with Previous Period - Compared to the 2025 mid-year report, the holdings of Central Huijin in the Huatai-PB CSI 300 ETF remained unchanged in the second half of 2025 [5] - The total number of shares held by Central Huijin in various broad-based ETFs, including E Fund CSI 300 ETF and Huaxia CSI 300 ETF, also remained stable [5] Market Trends - Recent data indicates a significant net outflow from broad-based ETFs, with over 220 billion yuan exiting the CSI 300 theme ETFs from January 12 to January 21, 2025 [5] - Other ETFs, including the CSI 1000 theme ETFs and the STAR 50 theme ETFs, also experienced substantial net outflows during the same period [5] Current ETF Holdings - As of January 21, 2025, the number of shares for major ETFs such as Huatai-PB CSI 300 ETF and Huaxia CSI 300 ETF has decreased compared to the holdings reported by Central Huijin at the end of 2025 [6][7] - The current shares for Huatai-PB CSI 300 ETF stand at 719.78 billion, down from Central Huijin's reported 735.13 billion shares at the end of 2025 [7]

基金经理是一只基金产品最核心的成员，能决定一只基金的投资方向、投资策略以及投资风格，基金经理出色的择时选股 能力和调研预测能力是基金业绩的有力保证，所以基金经理是投资者在选择基金产品时的重要依据。基金经理的变动很大 程度上会影响到基金产品未来的表现，是一个需要特别关注的信息。1.22日共有16位基金经理发生任职变动。 根据巨灵统计的数据，近30天（12.23-1.22）共有595只基金产品的基金经理发生离职。其中今天（1.22）日有18只基金产 品发布基金经理离职公告，涉及8名基金经理。从变动原因上来看，有5位基金经理是由于工作变动而从管理的7只基金产品 中离职。有1位基金经理是由于产品到期而从管理的1只基金产品中离职。有1位基金经理是由于辞职而从管理的2只基金产 品中离职。有1位基金经理是由于个人原因而从管理的8只基金产品中离职。 | | | 基金代码 | 公告日期 | | | | | --- | --- | --- | --- | --- | --- | --- | | ■開切/し | | 005607 | 2026/1/22 | 20: | | | | | 华宝中证500增强C | 005608 | 2 ...

Group 1 - The core point of the article is that Franklin Templeton Investments has increased its stake in Kingsoft Corporation Limited by purchasing 448,800 shares at a price of HKD 31.0103 per share, totaling approximately HKD 13.9174 million [1] - After the purchase, Franklin Templeton's total shareholding in Kingsoft has reached 70.256 million shares, representing a 5.02% ownership stake in the company [1]

Group 1 - The core point of the article is that Franklin Templeton Investments has increased its stake in Kingsoft Corporation by purchasing 448,800 shares at a price of HKD 31.0103 per share, totaling approximately HKD 13.9174 million [1] - After the purchase, Franklin Templeton's total holdings in Kingsoft reached 70.256 million shares, representing a 5.02% ownership stake in the company [1]

Group 1 - The core viewpoint of the news is that Jincheng Pharmaceutical's stock has increased by 5.37%, reaching a price of 15.88 yuan per share, with a trading volume of 1.81 billion yuan and a turnover rate of 3.15%, resulting in a total market capitalization of 60.96 billion yuan [1] - Jincheng Pharmaceutical, established on January 12, 2004, and listed on June 22, 2011, is located in Zibo City, Shandong Province. The company specializes in the research, production, and sales of pharmaceutical intermediates, active pharmaceutical ingredients, and finished formulations [1] - The revenue composition of Jincheng Pharmaceutical includes: formulation products at 34.59%, other pharmaceutical and chemical products at 26.61%, cephalosporin side-chain active ester series products at 21.88%, and biopharmaceuticals and specialty active pharmaceutical ingredients at 16.92% [1] Group 2 - Among the top circulating shareholders of Jincheng Pharmaceutical, a fund under the Fortune Fund ranks as a significant stakeholder. The Fortune Precision Medical Flexible Allocation Mixed A Fund (005176) entered the top ten circulating shareholders in the third quarter, holding 4.961 million shares, which accounts for 1.33% of the circulating shares [2] - The Fortune Precision Medical Flexible Allocation Mixed A Fund has a current scale of 3.491 billion yuan, with a year-to-date return of 4.34%, ranking 4447 out of 8844 in its category. Over the past year, it has achieved a return of 40.91%, ranking 2780 out of 8091, and since its inception, it has returned 212.06% [2] Group 3 - The fund manager of the Fortune Precision Medical Flexible Allocation Mixed A Fund is Zhao Wei, who has been in the position for 8 years and 218 days. The total asset scale of the fund is 9.845 billion yuan, with the best return during his tenure being 190.69% and the worst return being -13.15% [3]

Group 1 - The core viewpoint of the news is the performance and market position of Suzhou Dongwei Semiconductor Co., Ltd., which saw a stock price increase of 5.12% to 98.60 CNY per share, with a total market capitalization of 12.086 billion CNY [1] - Suzhou Dongwei Semiconductor, established on September 12, 2008, focuses on the research and sales of high-performance power devices, primarily serving industrial and automotive applications, with 95.24% of its revenue coming from power semiconductor products [1] - The company is located in Suzhou Industrial Park, Jiangsu Province, and was listed on February 10, 2022 [1] Group 2 - From the perspective of fund holdings, the Fuguo Fund has a significant position in Dongwei Semiconductor, with its Fuguo SSE Index ETF Link A/B (100053) being the fifth-largest holding, owning 402 shares [2] - The Fuguo SSE Index ETF Link A/B has a total asset size of 280 million CNY and has achieved a year-to-date return of 3.46%, ranking 3441 out of 5542 in its category [2] - The fund has delivered a one-year return of 27.65%, ranking 2700 out of 4243, and a cumulative return of 100.92% since its inception on January 30, 2011 [2] Group 3 - The fund managers of Fuguo SSE Index ETF Link A/B are Wang Baohe and Fang Min, with Wang having a tenure of 14 years and 329 days, managing assets totaling 10.562 billion CNY, and achieving a best return of 114.01% during his tenure [3] - Fang Min has a tenure of 11 years and 67 days, managing assets of 24.704 billion CNY, with a best return of 211.45% during his management period [3]

Group 1 - The core viewpoint of the news is that China Ruilin has seen a stock price increase of 5.89%, reaching 63.51 yuan per share, with a total market capitalization of 7.621 billion yuan [1] - China Ruilin Engineering Technology Co., Ltd. is based in Nanchang, Jiangxi Province, and was established on July 14, 1986, with its listing date on April 8, 2025 [1] - The company's main business involves providing engineering technical services across the entire industrial chain of non-ferrous metal mining, selection, smelting, and processing, as well as extending into environmental protection and municipal sectors [1] Group 2 - The fund "Fuguo SSE Sci-Tech Innovation Board 50 ETF Linked A" holds a small stake in China Ruilin, with 73 shares representing 0.0002% of the circulating shares, ranking as the sixth largest holding [2] - The fund has a total scale of 33.2785 million yuan and has achieved a year-to-date return of 9.84%, ranking 838 out of 5542 in its category [2] - The fund manager, Jin Zeyu, has been in position for 3 years and 180 days, with the fund's total asset scale at 17.865 billion yuan and a best return of 77.19% during his tenure [3]

Group 1 - The core point of the article highlights that Haisun Pharmaceutical experienced a 5% drop in stock price, trading at 50.30 yuan per share, with a total market capitalization of 6.036 billion yuan as of the report date [1] - Haisun Pharmaceutical, established on January 15, 2003, and listed on January 12, 2017, focuses on the research, production, and sales of chemical preparations, active pharmaceutical ingredients, and intermediates [1] - The company's revenue composition is primarily from cardiovascular drugs (87.12%), followed by antibiotics (5.69%), active pharmaceutical ingredients and intermediates (1.68%), digestive drugs (1.50%), antiviral drugs (1.47%), and other categories [1] Group 2 - Among the top circulating shareholders of Haisun Pharmaceutical, the Fuguo Fund's Fuguo Steady Growth Mixed A (010624) fund entered the top ten in the third quarter, holding 700,000 shares, which is 0.85% of the circulating shares [2] - The Fuguo Steady Growth Mixed A fund has a total scale of 6.13 billion yuan, with a year-to-date return of 5.37% and a one-year return of 36.61% [2] - The fund manager, Fan Yan, has been in the position for 10 years and 88 days, with the fund's best return during this period being 187.76% and the worst being -15.11% [3]